Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 11:13:1178230.
doi: 10.3389/fonc.2023.1178230. eCollection 2023.

Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy

Yu-Chun Song  1 , Zhou Huang  1   2 , Hui Fang  1 , Yu Tang  1 , Hao Jing  1 , Yong-Wen Song  1 , Jing Jin  1   3 , Yue-Ping Liu  1 , Bo Chen  1 , Yuan Tang  1 , Shu-Nan Qi  1 , Ning-Ning Lu  1 , Ning Li  1 , Ye-Xiong Li  1 , Shu-Lian Wang  1
Affiliations

Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy

Yu-Chun Song et al. Front Oncol. .

Abstract

Background: To compare recurrence and survival outcomes between breast-conserving surgery (BCS) and mastectomy after neoadjuvant chemotherapy (NACT).

Methods: The data of 730 patients who underwent NACT between 2000 and 2014 were retrospectively reviewed. A total of 104 (14.2%) patients received BCS and 626 (85.8%) received mastectomy. Locoregional recurrence (LRR), distant metastases (DM), disease-free survival (DFS), breast cancer-specific survival (BCSS), and overall survival (OS) were analyzed using the Kaplan-Meier method. The impact of BCS versus mastectomy on outcomes was assessed by multivariate Cox models. Inverse probability of treatment weighting (IPTW) was used to balance covariates between the two groups.

Results: The median follow-up of BCS and mastectomy groups were 86.5 and 87.4 months, respectively. There were significant differences in distribution of most baseline characteristics between two groups. Compared with those who underwent mastectomy, the patients with BCS had similar 5-year LRR, DM, and DFS rates, but had significantly higher 5-year BCSS (98.9% vs. 90.4%, P = 0.005) and OS (98.9% vs. 90.1%, P = 0.003) rates. Multivariate analysis also showed that BCS significantly improved BCSS (HR = 0.27, 95% CI: 0.08-0.85, P = 0.025) and OS (HR = 0.25, 95% CI: 0.08-0.79, P = 0.018). After IPTW adjustment, the LRR, DM, DFS, BCSS and OS between two groups had no significant differences.

Conclusions: The recurrence and survival outcomes are comparable with BCS and mastectomy. Thus, BCS is a safe treatment option for selected breast cancer patients after NACT.

Keywords: breast cancer; breast-conserving surgery; mastectomy; neoadjuvant chemotherapy; oncological outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
CONSORT diagram.
Figure 2
Figure 2
Comparison of LRR, DM, DFS, BCSS, and OS between the BCS and mastectomy groups before and after IPTW analysis. LRR (A), DM (C), DFS (E), BCSS (G), and OS (I) before IPTW analysis. LRR (B), DM (D), DFS (F), BCSS (H), and OS (J) after IPTW analysis. LRR, Locoregional recurrence; DM, distant metastasis; DFS, disease-free survival; BCSS, Breast cancer–specific survival; OS, overall survival; IPTW, inverse probability of treatment weighting.
See this image and copyright information in PMC

References

    1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med (2002) 347:1233–41. doi: 10.1056/NEJMoa022152 - DOI - PubMed
    1. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med (2002) 347:1227–32. doi: 10.1056/NEJMoa020989 - DOI - PubMed
    1. Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol (2012) 13:412–9. doi: 10.1016/s1470-2045(12)70042-6 - DOI - PubMed
    1. Curran D, van Dongen JP, Aaronson NK, Kiebert G, Fentiman IS, Mignolet F, et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC trial 10801. the European organization for research and treatment of cancer (EORTC), breast cancer Co-operative group (BCCG). Eur J Cancer (1998) 34:307–14. doi: 10.1016/s0959-8049(97)00312-2 - DOI - PubMed
    1. Arndt V, Stegmaier C, Ziegler H, Brenner H. Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study. J Cancer Res Clin Oncol (2008) 134:1311–8. doi: 10.1007/s00432-008-0418-y - DOI - PMC - PubMed

LinkOut - more resources